Across TCGA pan-cancer cohorts, BTLA mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of BTLA’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where BTLA mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BTLA is over-expressed in tumor.
LUAD and LSCC are the cancer types where BTLA tumor–normal differential expression is most reproducible.